#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0003] Vacuum induced healing of open wounds has recently been popularized by Kinetic Concepts, Inc. of San Antonio, Tex., by its commercially available V.A.C..RTM. product line.
1-1	0-1	[	_	_	
1-2	1-5	0003	_	_	
1-3	5-6	]	_	_	
1-4	7-13	Vacuum	_	_	
1-5	14-21	induced	_	_	
1-6	22-29	healing	_	_	
1-7	30-32	of	_	_	
1-8	33-37	open	_	_	
1-9	38-44	wounds	_	_	
1-10	45-48	has	_	_	
1-11	49-57	recently	_	_	
1-12	58-62	been	_	_	
1-13	63-74	popularized	_	_	
1-14	75-77	by	_	_	
1-15	78-85	Kinetic	_	_	
1-16	86-94	Concepts	_	_	
1-17	94-95	,	_	_	
1-18	96-99	Inc	_	_	
1-19	99-100	.	_	_	
1-20	101-103	of	_	_	
1-21	104-107	San	_	_	
1-22	108-115	Antonio	_	_	
1-23	115-116	,	_	_	
1-24	117-120	Tex	_	_	
1-25	120-121	.	_	_	
1-26	121-122	,	_	_	
1-27	123-125	by	_	_	
1-28	126-129	its	_	_	
1-29	130-142	commercially	_	_	
1-30	143-152	available	_	_	
1-31	153-158	V.A.C	_	_	
1-32	158-159	.	_	_	
1-33	159-160	.	_	_	
1-34	160-163	RTM	_	_	
1-35	163-164	.	_	_	
1-36	165-172	product	_	_	
1-37	173-177	line	_	_	
1-38	177-178	.	_	_	

#Text=The vacuum induced healing process has been described in commonly assigned U.S.
2-1	179-182	The	_	_	
2-2	183-189	vacuum	_	_	
2-3	190-197	induced	_	_	
2-4	198-205	healing	_	_	
2-5	206-213	process	_	_	
2-6	214-217	has	_	_	
2-7	218-222	been	_	_	
2-8	223-232	described	_	_	
2-9	233-235	in	_	_	
2-10	236-244	commonly	_	_	
2-11	245-253	assigned	_	_	
2-12	254-257	U.S	_	_	
2-13	257-258	.	_	_	

#Text=Pat.
3-1	259-262	Pat	_	_	
3-2	262-263	.	_	_	

#Text=No. 4,969,880 issued on Nov. 13, 1990 to Zamierowski, as well as its continuations and continuations in part, U.S.
4-1	264-266	No	_	_	
4-2	266-267	.	_	_	
4-3	268-277	4,969,880	_	_	
4-4	278-284	issued	_	_	
4-5	285-287	on	_	_	
4-6	288-291	Nov	_	_	
4-7	291-292	.	_	_	
4-8	293-295	13	_	_	
4-9	295-296	,	_	_	
4-10	297-301	1990	_	_	
4-11	302-304	to	_	_	
4-12	305-316	Zamierowski	_	_	
4-13	316-317	,	_	_	
4-14	318-320	as	_	_	
4-15	321-325	well	_	_	
4-16	326-328	as	_	_	
4-17	329-332	its	_	_	
4-18	333-346	continuations	_	_	
4-19	347-350	and	_	_	
4-20	351-364	continuations	_	_	
4-21	365-367	in	_	_	
4-22	368-372	part	_	_	
4-23	372-373	,	_	_	
4-24	374-377	U.S	_	_	
4-25	377-378	.	_	_	

#Text=Pat.
5-1	379-382	Pat	_	_	
5-2	382-383	.	_	_	

#Text=No. 5,100,396, issued on Mar. 31, 1992, U.S.
6-1	384-386	No	_	_	
6-2	386-387	.	_	_	
6-3	388-397	5,100,396	_	_	
6-4	397-398	,	_	_	
6-5	399-405	issued	_	_	
6-6	406-408	on	_	_	
6-7	409-412	Mar	_	_	
6-8	412-413	.	_	_	
6-9	414-416	31	_	_	
6-10	416-417	,	_	_	
6-11	418-422	1992	_	_	
6-12	422-423	,	_	_	
6-13	424-427	U.S	_	_	
6-14	427-428	.	_	_	

#Text=Pat.
7-1	429-432	Pat	_	_	
7-2	432-433	.	_	_	

#Text=No. 5,261,893, issued Nov. 16, 1993, and U.S.
8-1	434-436	No	_	_	
8-2	436-437	.	_	_	
8-3	438-447	5,261,893	_	_	
8-4	447-448	,	_	_	
8-5	449-455	issued	_	_	
8-6	456-459	Nov	_	_	
8-7	459-460	.	_	_	
8-8	461-463	16	_	_	
8-9	463-464	,	_	_	
8-10	465-469	1993	_	_	
8-11	469-470	,	_	_	
8-12	471-474	and	_	_	
8-13	475-478	U.S	_	_	
8-14	478-479	.	_	_	

#Text=Pat.
9-1	480-483	Pat	_	_	
9-2	483-484	.	_	_	

#Text=No. 5,527,293, issued Jun. 18, 1996, the disclosures of which are incorporated herein by this reference.
10-1	485-487	No	_	_	
10-2	487-488	.	_	_	
10-3	489-498	5,527,293	_	_	
10-4	498-499	,	_	_	
10-5	500-506	issued	_	_	
10-6	507-510	Jun	_	_	
10-7	510-511	.	_	_	
10-8	512-514	18	_	_	
10-9	514-515	,	_	_	
10-10	516-520	1996	_	_	
10-11	520-521	,	_	_	
10-12	522-525	the	_	_	
10-13	526-537	disclosures	_	_	
10-14	538-540	of	_	_	
10-15	541-546	which	_	_	
10-16	547-550	are	_	_	
10-17	551-563	incorporated	_	_	
10-18	564-570	herein	_	_	
10-19	571-573	by	_	_	
10-20	574-578	this	_	_	
10-21	579-588	reference	_	_	
10-22	588-589	.	_	_	

#Text=Further improvements and modifications of the vacuum induced healing process are also described in U.S.
11-1	590-597	Further	_	_	
11-2	598-610	improvements	_	_	
11-3	611-614	and	_	_	
11-4	615-628	modifications	_	_	
11-5	629-631	of	_	_	
11-6	632-635	the	_	_	
11-7	636-642	vacuum	_	_	
11-8	643-650	induced	_	_	
11-9	651-658	healing	_	_	
11-10	659-666	process	_	_	
11-11	667-670	are	_	_	
11-12	671-675	also	_	_	
11-13	676-685	described	_	_	
11-14	686-688	in	_	_	
11-15	689-692	U.S	_	_	
11-16	692-693	.	_	_	

#Text=Pat.
12-1	694-697	Pat	_	_	
12-2	697-698	.	_	_	

#Text=No. 6,071,267, issued on Jun. 6, 2000 to Zamierowski and U.S.
13-1	699-701	No	_	_	
13-2	701-702	.	_	_	
13-3	703-712	6,071,267	_	_	
13-4	712-713	,	_	_	
13-5	714-720	issued	_	_	
13-6	721-723	on	_	_	
13-7	724-727	Jun	_	_	
13-8	727-728	.	_	_	
13-9	729-730	6	_	_	
13-10	730-731	,	_	_	
13-11	732-736	2000	_	_	
13-12	737-739	to	_	_	
13-13	740-751	Zamierowski	_	_	
13-14	752-755	and	_	_	
13-15	756-759	U.S	_	_	
13-16	759-760	.	_	_	

#Text=Pat.
14-1	761-764	Pat	_	_	
14-2	764-765	.	_	_	

#Text=Nos. 5,636,643 and 5,645,081 issued to Argenta et al. on Jun. 10, 1997 and Jul. 8, 1997 respectively, the disclosures of which are incorporated by reference as though fully set forth herein.
#Text=[0004] Substantial work has also been performed relating to the creation of bioabsorbable and includable, cell growth enhancing matrices, lattices, or scaffolds.
15-1	766-769	Nos	_	_	
15-2	769-770	.	_	_	
15-3	771-780	5,636,643	_	_	
15-4	781-784	and	_	_	
15-5	785-794	5,645,081	_	_	
15-6	795-801	issued	_	_	
15-7	802-804	to	_	_	
15-8	805-812	Argenta	_	_	
15-9	813-815	et	_	_	
15-10	816-818	al	_	_	
15-11	818-819	.	_	_	
15-12	820-822	on	_	_	
15-13	823-826	Jun	_	_	
15-14	826-827	.	_	_	
15-15	828-830	10	_	_	
15-16	830-831	,	_	_	
15-17	832-836	1997	_	_	
15-18	837-840	and	_	_	
15-19	841-844	Jul	_	_	
15-20	844-845	.	_	_	
15-21	846-847	8	_	_	
15-22	847-848	,	_	_	
15-23	849-853	1997	_	_	
15-24	854-866	respectively	_	_	
15-25	866-867	,	_	_	
15-26	868-871	the	_	_	
15-27	872-883	disclosures	_	_	
15-28	884-886	of	_	_	
15-29	887-892	which	_	_	
15-30	893-896	are	_	_	
15-31	897-909	incorporated	_	_	
15-32	910-912	by	_	_	
15-33	913-922	reference	_	_	
15-34	923-925	as	_	_	
15-35	926-932	though	_	_	
15-36	933-938	fully	_	_	
15-37	939-942	set	_	_	
15-38	943-948	forth	_	_	
15-39	949-955	herein	_	_	
15-40	955-956	.	_	_	
15-41	957-958	[	_	_	
15-42	958-962	0004	_	_	
15-43	962-963	]	_	_	
15-44	964-975	Substantial	_	_	
15-45	976-980	work	_	_	
15-46	981-984	has	_	_	
15-47	985-989	also	_	_	
15-48	990-994	been	_	_	
15-49	995-1004	performed	_	_	
15-50	1005-1013	relating	_	_	
15-51	1014-1016	to	_	_	
15-52	1017-1020	the	_	_	
15-53	1021-1029	creation	_	_	
15-54	1030-1032	of	_	_	
15-55	1033-1046	bioabsorbable	_	_	
15-56	1047-1050	and	_	_	
15-57	1051-1061	includable	_	_	
15-58	1061-1062	,	_	_	
15-59	1063-1067	cell	_	_	
15-60	1068-1074	growth	_	_	
15-61	1075-1084	enhancing	_	_	
15-62	1085-1093	matrices	_	_	
15-63	1093-1094	,	_	_	
15-64	1095-1103	lattices	_	_	
15-65	1103-1104	,	_	_	
15-66	1105-1107	or	_	_	
15-67	1108-1117	scaffolds	_	_	
15-68	1117-1118	.	_	_	

#Text=Exemplary U.S. patents known to applicant include Kemp et al.
16-1	1119-1128	Exemplary	_	_	
16-2	1129-1132	U.S	_	_	
16-3	1132-1133	.	_	_	
16-4	1134-1141	patents	_	_	
16-5	1142-1147	known	_	_	
16-6	1148-1150	to	_	_	
16-7	1151-1160	applicant	_	_	
16-8	1161-1168	include	_	_	
16-9	1169-1173	Kemp	_	_	
16-10	1174-1176	et	_	_	
16-11	1177-1179	al	_	_	
16-12	1179-1180	.	_	_	

#Text=U.S.
17-1	1181-1184	U.S	_	_	
17-2	1184-1185	.	_	_	

#Text=Pat.
18-1	1186-1189	Pat	_	_	
18-2	1189-1190	.	_	_	

#Text=No. 5,256,418 issued Oct. 26, 1993; Chatelier et al.
19-1	1191-1193	No	_	_	
19-2	1193-1194	.	_	_	
19-3	1195-1204	5,256,418	_	_	
19-4	1205-1211	issued	_	_	
19-5	1212-1215	Oct	_	_	
19-6	1215-1216	.	_	_	
19-7	1217-1219	26	_	_	
19-8	1219-1220	,	_	_	
19-9	1221-1225	1993	_	_	
19-10	1225-1226	;	_	_	
19-11	1227-1236	Chatelier	_	_	
19-12	1237-1239	et	_	_	
19-13	1240-1242	al	_	_	
19-14	1242-1243	.	_	_	

#Text=U.S.
20-1	1244-1247	U.S	_	_	
20-2	1247-1248	.	_	_	

#Text=Pat.
21-1	1249-1252	Pat	_	_	
21-2	1252-1253	.	_	_	

#Text=No. 5,449,383 issued Sep. 12, 1995; Bennett et al. 5,578,662 issued Nov. 26, 1996; and two patents issued to Yasukawa et al.
22-1	1254-1256	No	_	_	
22-2	1256-1257	.	_	_	
22-3	1258-1267	5,449,383	_	_	
22-4	1268-1274	issued	_	_	
22-5	1275-1278	Sep	_	_	
22-6	1278-1279	.	_	_	
22-7	1280-1282	12	_	_	
22-8	1282-1283	,	_	_	
22-9	1284-1288	1995	_	_	
22-10	1288-1289	;	_	_	
22-11	1290-1297	Bennett	_	_	
22-12	1298-1300	et	_	_	
22-13	1301-1303	al	_	_	
22-14	1303-1304	.	_	_	
22-15	1305-1314	5,578,662	_	_	
22-16	1315-1321	issued	_	_	
22-17	1322-1325	Nov	_	_	
22-18	1325-1326	.	_	_	
22-19	1327-1329	26	_	_	
22-20	1329-1330	,	_	_	
22-21	1331-1335	1996	_	_	
22-22	1335-1336	;	_	_	
22-23	1337-1340	and	_	_	
22-24	1341-1344	two	_	_	
22-25	1345-1352	patents	_	_	
22-26	1353-1359	issued	_	_	
22-27	1360-1362	to	_	_	
22-28	1363-1371	Yasukawa	_	_	
22-29	1372-1374	et	_	_	
22-30	1375-1377	al	_	_	
22-31	1377-1378	.	_	_	

#Text=U.S.
23-1	1379-1382	U.S	_	_	
23-2	1382-1383	.	_	_	

#Text=Pat.
24-1	1384-1387	Pat	_	_	
24-2	1387-1388	.	_	_	

#Text=No. 5,629,186 issued May 13, 1997 and U.S.
25-1	1389-1391	No	_	_	
25-2	1391-1392	.	_	_	
25-3	1393-1402	5,629,186	_	_	
25-4	1403-1409	issued	_	_	
25-5	1410-1413	May	_	_	
25-6	1414-1416	13	_	_	
25-7	1416-1417	,	_	_	
25-8	1418-1422	1997	_	_	
25-9	1423-1426	and	_	_	
25-10	1427-1430	U.S	_	_	
25-11	1430-1431	.	_	_	

#Text=Pat.
26-1	1432-1435	Pat	_	_	
26-2	1435-1436	.	_	_	

#Text=No. 5,780,281 issued Jul. 14, 1998, both from a common parent application; the disclosures of which are incorporated by reference herein.
#Text=[0005] As is well known to those of ordinary skill in the art, closure of surface wounds involves the inward migration of epithelial and subcutaneous tissue adjacent the wound.
27-1	1437-1439	No	_	_	
27-2	1439-1440	.	_	_	
27-3	1441-1450	5,780,281	_	_	
27-4	1451-1457	issued	_	_	
27-5	1458-1461	Jul	_	_	
27-6	1461-1462	.	_	_	
27-7	1463-1465	14	_	_	
27-8	1465-1466	,	_	_	
27-9	1467-1471	1998	_	_	
27-10	1471-1472	,	_	_	
27-11	1473-1477	both	_	_	
27-12	1478-1482	from	_	_	
27-13	1483-1484	a	_	_	
27-14	1485-1491	common	_	_	
27-15	1492-1498	parent	_	_	
27-16	1499-1510	application	_	_	
27-17	1510-1511	;	_	_	
27-18	1512-1515	the	_	_	
27-19	1516-1527	disclosures	_	_	
27-20	1528-1530	of	_	_	
27-21	1531-1536	which	_	_	
27-22	1537-1540	are	_	_	
27-23	1541-1553	incorporated	_	_	
27-24	1554-1556	by	_	_	
27-25	1557-1566	reference	_	_	
27-26	1567-1573	herein	_	_	
27-27	1573-1574	.	_	_	
27-28	1575-1576	[	_	_	
27-29	1576-1580	0005	_	_	
27-30	1580-1581	]	_	_	
27-31	1582-1584	As	_	_	
27-32	1585-1587	is	_	_	
27-33	1588-1592	well	_	_	
27-34	1593-1598	known	_	_	
27-35	1599-1601	to	_	_	
27-36	1602-1607	those	_	_	
27-37	1608-1610	of	_	_	
27-38	1611-1619	ordinary	_	_	
27-39	1620-1625	skill	_	_	
27-40	1626-1628	in	_	_	
27-41	1629-1632	the	_	_	
27-42	1633-1636	art	_	_	
27-43	1636-1637	,	_	_	
27-44	1638-1645	closure	_	_	
27-45	1646-1648	of	_	_	
27-46	1649-1656	surface	_	_	
27-47	1657-1663	wounds	_	_	
27-48	1664-1672	involves	_	_	
27-49	1673-1676	the	_	_	
27-50	1677-1683	inward	_	_	
27-51	1684-1693	migration	_	_	
27-52	1694-1696	of	_	_	
27-53	1697-1707	epithelial	_	_	
27-54	1708-1711	and	_	_	
27-55	1712-1724	subcutaneous	_	_	
27-56	1725-1731	tissue	_	_	
27-57	1732-1740	adjacent	_	_	
27-58	1741-1744	the	_	_	
27-59	1745-1750	wound	_	_	
27-60	1750-1751	.	_	_	

#Text=This migration is ordinarily assisted through the inflammatory process, whereby blood flow is increased and various functional cell types are activated.
28-1	1752-1756	This	_	_	
28-2	1757-1766	migration	_	_	
28-3	1767-1769	is	_	_	
28-4	1770-1780	ordinarily	_	_	
28-5	1781-1789	assisted	_	_	
28-6	1790-1797	through	_	_	
28-7	1798-1801	the	_	_	
28-8	1802-1814	inflammatory	_	_	
28-9	1815-1822	process	_	_	
28-10	1822-1823	,	_	_	
28-11	1824-1831	whereby	_	_	
28-12	1832-1837	blood	_	_	
28-13	1838-1842	flow	_	_	
28-14	1843-1845	is	_	_	
28-15	1846-1855	increased	_	_	
28-16	1856-1859	and	_	_	
28-17	1860-1867	various	_	_	
28-18	1868-1878	functional	_	_	
28-19	1879-1883	cell	_	_	
28-20	1884-1889	types	_	_	
28-21	1890-1893	are	_	_	
28-22	1894-1903	activated	_	_	
28-23	1903-1904	.	_	_	

#Text=Through the inflammatory process, blood flow through damaged or broken vessels is stopped by capillary level occlusion; thereafter, cleanup and rebuilding operations may begin.
29-1	1905-1912	Through	*[1]	30-3[2_1]	
29-2	1913-1916	the	*[1]	_	
29-3	1917-1929	inflammatory	*[1]	_	
29-4	1930-1937	process	*[1]	_	
29-5	1937-1938	,	*[1]	_	
29-6	1939-1944	blood	*[1]	_	
29-7	1945-1949	flow	*[1]	_	
29-8	1950-1957	through	*[1]	_	
29-9	1958-1965	damaged	*[1]	_	
29-10	1966-1968	or	*[1]	_	
29-11	1969-1975	broken	*[1]	_	
29-12	1976-1983	vessels	*[1]	_	
29-13	1984-1986	is	*[1]	_	
29-14	1987-1994	stopped	*[1]	_	
29-15	1995-1997	by	*[1]	_	
29-16	1998-2007	capillary	*[1]	_	
29-17	2008-2013	level	*[1]	_	
29-18	2014-2023	occlusion	*[1]	_	
29-19	2023-2024	;	*[1]	_	
29-20	2025-2035	thereafter	*[1]	_	
29-21	2035-2036	,	*[1]	_	
29-22	2037-2044	cleanup	*[1]	_	
29-23	2045-2048	and	*[1]	_	
29-24	2049-2059	rebuilding	*[1]	_	
29-25	2060-2070	operations	*[1]	_	
29-26	2071-2074	may	*[1]	_	
29-27	2075-2080	begin	*[1]	_	
29-28	2080-2081	.	*[1]	_	

#Text=Unfortunately, this process is hampered when a wound is large or has become infected.
30-1	2082-2095	Unfortunately	_	_	
30-2	2095-2096	,	_	_	
30-3	2097-2101	this	*[2]	_	
30-4	2102-2109	process	*[2]	_	
30-5	2110-2112	is	_	_	
30-6	2113-2121	hampered	_	_	
30-7	2122-2126	when	_	_	
30-8	2127-2128	a	_	_	
30-9	2129-2134	wound	_	_	
30-10	2135-2137	is	_	_	
30-11	2138-2143	large	_	_	
30-12	2144-2146	or	_	_	
30-13	2147-2150	has	_	_	
30-14	2151-2157	become	_	_	
30-15	2158-2166	infected	_	_	
30-16	2166-2167	.	_	_	

#Text=In such wounds, a zone of stasis (i.e. an area in which localized swelling of tissue restricts the flow of blood to the tissues) forms near the surface of the wound.
#Text=[0006] Without sufficient blood flow, the epithelial and subcutaneous tissues surrounding the wound not only receive diminished oxygen and nutrients, but also are also less able to successfully fight bacterial infection and thus are less able to naturally close the wound.
31-1	2168-2170	In	_	_	
31-2	2171-2175	such	_	_	
31-3	2176-2182	wounds	_	_	
31-4	2182-2183	,	_	_	
31-5	2184-2185	a	_	_	
31-6	2186-2190	zone	_	_	
31-7	2191-2193	of	_	_	
31-8	2194-2200	stasis	_	_	
31-9	2201-2202	(	_	_	
31-10	2202-2205	i.e	_	_	
31-11	2205-2206	.	_	_	
31-12	2207-2209	an	_	_	
31-13	2210-2214	area	_	_	
31-14	2215-2217	in	_	_	
31-15	2218-2223	which	_	_	
31-16	2224-2233	localized	_	_	
31-17	2234-2242	swelling	_	_	
31-18	2243-2245	of	_	_	
31-19	2246-2252	tissue	_	_	
31-20	2253-2262	restricts	_	_	
31-21	2263-2266	the	_	_	
31-22	2267-2271	flow	_	_	
31-23	2272-2274	of	_	_	
31-24	2275-2280	blood	_	_	
31-25	2281-2283	to	_	_	
31-26	2284-2287	the	_	_	
31-27	2288-2295	tissues	_	_	
31-28	2295-2296	)	_	_	
31-29	2297-2302	forms	_	_	
31-30	2303-2307	near	_	_	
31-31	2308-2311	the	_	_	
31-32	2312-2319	surface	_	_	
31-33	2320-2322	of	_	_	
31-34	2323-2326	the	_	_	
31-35	2327-2332	wound	_	_	
31-36	2332-2333	.	_	_	
31-37	2334-2335	[	_	_	
31-38	2335-2339	0006	_	_	
31-39	2339-2340	]	_	_	
31-40	2341-2348	Without	_	_	
31-41	2349-2359	sufficient	_	_	
31-42	2360-2365	blood	_	_	
31-43	2366-2370	flow	_	_	
31-44	2370-2371	,	_	_	
31-45	2372-2375	the	_	_	
31-46	2376-2386	epithelial	_	_	
31-47	2387-2390	and	_	_	
31-48	2391-2403	subcutaneous	_	_	
31-49	2404-2411	tissues	_	_	
31-50	2412-2423	surrounding	_	_	
31-51	2424-2427	the	_	_	
31-52	2428-2433	wound	_	_	
31-53	2434-2437	not	_	_	
31-54	2438-2442	only	_	_	
31-55	2443-2450	receive	_	_	
31-56	2451-2461	diminished	_	_	
31-57	2462-2468	oxygen	_	_	
31-58	2469-2472	and	_	_	
31-59	2473-2482	nutrients	_	_	
31-60	2482-2483	,	_	_	
31-61	2484-2487	but	_	_	
31-62	2488-2492	also	_	_	
31-63	2493-2496	are	_	_	
31-64	2497-2501	also	_	_	
31-65	2502-2506	less	_	_	
31-66	2507-2511	able	_	_	
31-67	2512-2514	to	_	_	
31-68	2515-2527	successfully	_	_	
31-69	2528-2533	fight	_	_	
31-70	2534-2543	bacterial	_	_	
31-71	2544-2553	infection	_	_	
31-72	2554-2557	and	_	_	
31-73	2558-2562	thus	_	_	
31-74	2563-2566	are	_	_	
31-75	2567-2571	less	_	_	
31-76	2572-2576	able	_	_	
31-77	2577-2579	to	_	_	
31-78	2580-2589	naturally	_	_	
31-79	2590-2595	close	_	_	
31-80	2596-2599	the	_	_	
31-81	2600-2605	wound	_	_	
31-82	2605-2606	.	_	_	

#Text=Until the advent of vacuum induced therapy, such difficult wounds were addressed only through the use of sutures or staples.
32-1	2607-2612	Until	_	_	
32-2	2613-2616	the	_	_	
32-3	2617-2623	advent	_	_	
32-4	2624-2626	of	_	_	
32-5	2627-2633	vacuum	_	_	
32-6	2634-2641	induced	_	_	
32-7	2642-2649	therapy	_	_	
32-8	2649-2650	,	_	_	
32-9	2651-2655	such	_	_	
32-10	2656-2665	difficult	_	_	
32-11	2666-2672	wounds	_	_	
32-12	2673-2677	were	_	_	
32-13	2678-2687	addressed	_	_	
32-14	2688-2692	only	_	_	
32-15	2693-2700	through	_	_	
32-16	2701-2704	the	_	_	
32-17	2705-2708	use	_	_	
32-18	2709-2711	of	_	_	
32-19	2712-2719	sutures	_	_	
32-20	2720-2722	or	_	_	
32-21	2723-2730	staples	_	_	
32-22	2730-2731	.	_	_	

#Text=Although still widely practiced and often effective, such mechanical closure techniques suffer a major disadvantage in that they produce tension on the skin tissue adjacent the wound.
33-1	2732-2740	Although	_	_	
33-2	2741-2746	still	_	_	
33-3	2747-2753	widely	_	_	
33-4	2754-2763	practiced	_	_	
33-5	2764-2767	and	_	_	
33-6	2768-2773	often	_	_	
33-7	2774-2783	effective	_	_	
33-8	2783-2784	,	_	_	
33-9	2785-2789	such	_	_	
33-10	2790-2800	mechanical	_	_	
33-11	2801-2808	closure	_	_	
33-12	2809-2819	techniques	_	_	
33-13	2820-2826	suffer	_	_	
33-14	2827-2828	a	_	_	
33-15	2829-2834	major	_	_	
33-16	2835-2847	disadvantage	_	_	
33-17	2848-2850	in	_	_	
33-18	2851-2855	that	_	_	
33-19	2856-2860	they	_	_	
33-20	2861-2868	produce	_	_	
33-21	2869-2876	tension	_	_	
33-22	2877-2879	on	_	_	
33-23	2880-2883	the	_	_	
33-24	2884-2888	skin	_	_	
33-25	2889-2895	tissue	_	_	
33-26	2896-2904	adjacent	_	_	
33-27	2905-2908	the	_	_	
33-28	2909-2914	wound	_	_	
33-29	2914-2915	.	_	_	

#Text=In particular, the tensile force required in order to achieve closure using sutures or staples may cause very high localized stresses at the suture or staple insertion point.
34-1	2916-2918	In	_	_	
34-2	2919-2929	particular	_	_	
34-3	2929-2930	,	_	_	
34-4	2931-2934	the	_	_	
34-5	2935-2942	tensile	_	_	
34-6	2943-2948	force	_	_	
34-7	2949-2957	required	_	_	
34-8	2958-2960	in	_	_	
34-9	2961-2966	order	_	_	
34-10	2967-2969	to	_	_	
34-11	2970-2977	achieve	_	_	
34-12	2978-2985	closure	_	_	
34-13	2986-2991	using	_	_	
34-14	2992-2999	sutures	_	_	
34-15	3000-3002	or	_	_	
34-16	3003-3010	staples	_	_	
34-17	3011-3014	may	_	_	
34-18	3015-3020	cause	_	_	
34-19	3021-3025	very	_	_	
34-20	3026-3030	high	_	_	
34-21	3031-3040	localized	_	_	
34-22	3041-3049	stresses	_	_	
34-23	3050-3052	at	_	_	
34-24	3053-3056	the	_	_	
34-25	3057-3063	suture	_	_	
34-26	3064-3066	or	_	_	
34-27	3067-3073	staple	_	_	
34-28	3074-3083	insertion	_	_	
34-29	3084-3089	point	_	_	
34-30	3089-3090	.	_	_	

#Text=These stresses commonly result in the rupture of the tissue at the insertion points, which can eventually cause wound dehiscence and additional tissue loss.
#Text=[0007] Additionally, some wounds harden and inflame to such a degree due to infection that closure by stapling or suturing is not feasible.
35-1	3091-3096	These	_	_	
35-2	3097-3105	stresses	_	_	
35-3	3106-3114	commonly	_	_	
35-4	3115-3121	result	_	_	
35-5	3122-3124	in	_	_	
35-6	3125-3128	the	_	_	
35-7	3129-3136	rupture	_	_	
35-8	3137-3139	of	_	_	
35-9	3140-3143	the	_	_	
35-10	3144-3150	tissue	_	_	
35-11	3151-3153	at	_	_	
35-12	3154-3157	the	_	_	
35-13	3158-3167	insertion	_	_	
35-14	3168-3174	points	_	_	
35-15	3174-3175	,	_	_	
35-16	3176-3181	which	_	_	
35-17	3182-3185	can	_	_	
35-18	3186-3196	eventually	_	_	
35-19	3197-3202	cause	_	_	
35-20	3203-3208	wound	_	_	
35-21	3209-3219	dehiscence	_	_	
35-22	3220-3223	and	_	_	
35-23	3224-3234	additional	_	_	
35-24	3235-3241	tissue	_	_	
35-25	3242-3246	loss	_	_	
35-26	3246-3247	.	_	_	
35-27	3248-3249	[	_	_	
35-28	3249-3253	0007	_	_	
35-29	3253-3254	]	_	_	
35-30	3255-3267	Additionally	_	_	
35-31	3267-3268	,	_	_	
35-32	3269-3273	some	_	_	
35-33	3274-3280	wounds	_	_	
35-34	3281-3287	harden	_	_	
35-35	3288-3291	and	_	_	
35-36	3292-3299	inflame	_	_	
35-37	3300-3302	to	_	_	
35-38	3303-3307	such	_	_	
35-39	3308-3309	a	_	_	
35-40	3310-3316	degree	_	_	
35-41	3317-3320	due	_	_	
35-42	3321-3323	to	_	_	
35-43	3324-3333	infection	_	_	
35-44	3334-3338	that	_	_	
35-45	3339-3346	closure	_	_	
35-46	3347-3349	by	_	_	
35-47	3350-3358	stapling	_	_	
35-48	3359-3361	or	_	_	
35-49	3362-3370	suturing	_	_	
35-50	3371-3373	is	_	_	
35-51	3374-3377	not	_	_	
35-52	3378-3386	feasible	_	_	
35-53	3386-3387	.	_	_	

#Text=Wounds not reparable by suturing or stapling generally require prolonged hospitalization, with its attendant high cost, and major surgical procedures, such as grafts of surrounding tissues.
36-1	3388-3394	Wounds	_	_	
36-2	3395-3398	not	_	_	
36-3	3399-3408	reparable	_	_	
36-4	3409-3411	by	_	_	
36-5	3412-3420	suturing	_	_	
36-6	3421-3423	or	_	_	
36-7	3424-3432	stapling	_	_	
36-8	3433-3442	generally	_	_	
36-9	3443-3450	require	_	_	
36-10	3451-3460	prolonged	_	_	
36-11	3461-3476	hospitalization	_	_	
36-12	3476-3477	,	_	_	
36-13	3478-3482	with	_	_	
36-14	3483-3486	its	_	_	
36-15	3487-3496	attendant	_	_	
36-16	3497-3501	high	_	_	
36-17	3502-3506	cost	_	_	
36-18	3506-3507	,	_	_	
36-19	3508-3511	and	_	_	
36-20	3512-3517	major	_	_	
36-21	3518-3526	surgical	_	_	
36-22	3527-3537	procedures	_	_	
36-23	3537-3538	,	_	_	
36-24	3539-3543	such	_	_	
36-25	3544-3546	as	_	_	
36-26	3547-3553	grafts	_	_	
36-27	3554-3556	of	_	_	
36-28	3557-3568	surrounding	_	_	
36-29	3569-3576	tissues	_	_	
36-30	3576-3577	.	_	_	

#Text=Examples of wounds not readily treatable with staples or suturing include large, deep, open wounds; decubitus ulcers; ulcers resulting from chronic osteomyelitis; and partial thickness burns that subsequently develop into full thickness bums.
37-1	3578-3586	Examples	_	_	
37-2	3587-3589	of	_	_	
37-3	3590-3596	wounds	_	_	
37-4	3597-3600	not	_	_	
37-5	3601-3608	readily	_	_	
37-6	3609-3618	treatable	_	_	
37-7	3619-3623	with	_	_	
37-8	3624-3631	staples	_	_	
37-9	3632-3634	or	_	_	
37-10	3635-3643	suturing	_	_	
37-11	3644-3651	include	_	_	
37-12	3652-3657	large	_	_	
37-13	3657-3658	,	_	_	
37-14	3659-3663	deep	_	_	
37-15	3663-3664	,	_	_	
37-16	3665-3669	open	_	_	
37-17	3670-3676	wounds	_	_	
37-18	3676-3677	;	_	_	
37-19	3678-3687	decubitus	_	_	
37-20	3688-3694	ulcers	_	_	
37-21	3694-3695	;	_	_	
37-22	3696-3702	ulcers	_	_	
37-23	3703-3712	resulting	_	_	
37-24	3713-3717	from	_	_	
37-25	3718-3725	chronic	_	_	
37-26	3726-3739	osteomyelitis	_	_	
37-27	3739-3740	;	_	_	
37-28	3741-3744	and	_	_	
37-29	3745-3752	partial	_	_	
37-30	3753-3762	thickness	_	_	
37-31	3763-3768	burns	_	_	
37-32	3769-3773	that	_	_	
37-33	3774-3786	subsequently	_	_	
37-34	3787-3794	develop	_	_	
37-35	3795-3799	into	_	_	
37-36	3800-3804	full	_	_	
37-37	3805-3814	thickness	_	_	
37-38	3815-3819	bums	_	_	
37-39	3819-3820	.	_	_	
